Get the Stockscreener App
13.57
2.90%
-0.405
Eyepoint Pharmaceuticals Inc stock is traded at $13.57, with a volume of 659.11K.
It is down -2.90% in the last 24 hours and up +0.15% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$13.97
Open:
$13.98
24h Volume:
659.11K
Relative Volume:
0.81
Market Cap:
$935.35M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-7.456
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
-1.17%
1M Performance:
+0.15%
6M Performance:
+182.71%
1Y Performance:
+64.68%
1-Day Range:
$13.50
$14.11
1-Week Range:
$12.99
$14.36
52-Week Range:
$3.91
$14.91
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
13.57 | 963.26M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Is EyePoint Pharmaceuticals Inc. (PV3B) stock a buy before new product rolloutExit Point & Momentum Based Trading Ideas - newser.com
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Eyepoint Pharmaceuticals' (EYPT) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
How EyePoint Pharmaceuticals Inc. (PV3B) stock behaves in tightening cyclesVolume Spike & Advanced Technical Signal Analysis - newser.com
Is a relief rally coming for EyePoint Pharmaceuticals Inc. holdersJuly 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - newser.com
What downside risks could hit EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Market Trends & Low Drawdown Investment Ideas - newser.com
Using Bollinger Bands to evaluate EyePoint Pharmaceuticals Inc.2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
What analysts say about EyePoint Pharmaceuticals Inc stockReal-Time Stock Alerts & Take Advantage of Momentum Stocks - earlytimes.in
EyePoint Pharmaceuticals Hits New 52-Week High of $14.90 - Markets Mojo
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain margin levelsCEO Change & Daily Stock Trend Reports - newser.com
Candlestick signals on EyePoint Pharmaceuticals Inc. stock todayQuarterly Trade Review & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-03 02:01:33 - newser.com
Sentiment analysis tools applied to EyePoint Pharmaceuticals Inc.Trade Volume Summary & Low Drawdown Momentum Ideas - newser.com
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
EyePoint stock rating reiterated at Outperform by Mizuho amid competitor review - Investing.com
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Hits New 1-Year HighHere's Why - MarketBeat
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 4%Time to Buy? - MarketBeat
Detecting support and resistance levels for EyePoint Pharmaceuticals Inc.July 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Published on: 2025-09-29 08:12:16 - newser.com
Will earnings trigger a reversal in EyePoint Pharmaceuticals Inc.Portfolio Return Report & Detailed Earnings Play Alerts - newser.com
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockLong-Term Investment Plans & Low Cost Wealth Building - earlytimes.in
Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Published on: 2025-09-22 08:23:21 - خودرو بانک
Published on: 2025-09-20 23:35:30 - خودرو بانک
Death Cross: What are analysts price targets for EyePoint Pharmaceuticals IncTrade Exit Summary & Reliable Price Action Trade Plans - خودرو بانک
Sentiment Review: Can EyePoint Pharmaceuticals Inc. outperform under higher oil pricesPortfolio Return Report & Fast Entry and Exit Trade Plans - خودرو بانک
Is EyePoint Pharmaceuticals (NASDAQ:EYPT) In A Good Position To Invest In Growth? - Yahoo Finance
EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring A 150% Potential Upside - DirectorsTalk Interviews
Why is EyePoint Pharmaceuticals Inc stock going upSell Signal & Growth Oriented Trading Recommendations - خودرو بانک
Resistance Check: Should I invest in EyePoint Pharmaceuticals Inc. before earningsWeekly Earnings Recap & Stock Timing and Entry Methods - خودرو بانک
US Market Wrap: Why is EyePoint Pharmaceuticals Inc stock going up2025 Key Lessons & Real-Time Buy Signal Notifications - خودرو بانک
Dynamic Technology Lab Private Ltd Grows Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyepoint Pharmaceuticals Inc Stock (EYPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Jul 10 '25 |
Option Exercise |
0.00 |
11,111 |
0 |
216,547 |
| Duker Jay S. | President and CEO |
Jul 10 '25 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Elston George | Chief Financial Officer |
May 25 '25 |
Option Exercise |
0.00 |
7,500 |
0 |
83,050 |
| Zaderej Karen L. | Director |
May 19 '25 |
Buy |
5.99 |
5,000 |
29,950 |
36,500 |
| Zaderej Karen L. | Director |
May 16 '25 |
Buy |
5.81 |
5,000 |
29,050 |
31,500 |
| Zaderej Karen L. | Director |
May 15 '25 |
Buy |
5.47 |
5,000 |
27,350 |
26,500 |
| Zaderej Karen L. | Director |
May 14 '25 |
Buy |
5.42 |
5,000 |
27,100 |
21,500 |
| Elston George | Chief Financial Officer |
Feb 09 '25 |
Option Exercise |
0.00 |
5,834 |
0 |
75,550 |
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):